JP2009079016A - Raw material for cosmetic and cosmetic - Google Patents
Raw material for cosmetic and cosmetic Download PDFInfo
- Publication number
- JP2009079016A JP2009079016A JP2007250957A JP2007250957A JP2009079016A JP 2009079016 A JP2009079016 A JP 2009079016A JP 2007250957 A JP2007250957 A JP 2007250957A JP 2007250957 A JP2007250957 A JP 2007250957A JP 2009079016 A JP2009079016 A JP 2009079016A
- Authority
- JP
- Japan
- Prior art keywords
- raw material
- cosmetic
- skin
- ability
- proteoglycan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 48
- 239000002994 raw material Substances 0.000 title claims abstract description 37
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 39
- 241000251730 Chondrichthyes Species 0.000 claims abstract description 24
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 claims abstract description 23
- 102000008186 Collagen Human genes 0.000 claims abstract description 23
- 108010035532 Collagen Proteins 0.000 claims abstract description 23
- 229920001436 collagen Polymers 0.000 claims abstract description 22
- 210000000845 cartilage Anatomy 0.000 claims abstract description 21
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 18
- YUZJJFWCXJDFOQ-UHFFFAOYSA-K manganese(3+);2-methoxy-6-[2-[(3-methoxy-2-oxidophenyl)methylideneamino]ethyliminomethyl]phenolate;chloride Chemical compound [Cl-].[Mn+3].COC1=CC=CC(C=NCCN=CC=2C(=C(OC)C=CC=2)[O-])=C1[O-] YUZJJFWCXJDFOQ-UHFFFAOYSA-K 0.000 claims abstract description 14
- 229940091557 ethylbisiminomethylguaiacol manganese chloride Drugs 0.000 claims abstract description 12
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 15
- 230000037303 wrinkles Effects 0.000 abstract description 7
- 206010013786 Dry skin Diseases 0.000 abstract description 3
- 230000037336 dry skin Effects 0.000 abstract 1
- 238000007665 sagging Methods 0.000 abstract 1
- 102000016611 Proteoglycans Human genes 0.000 description 23
- 108010067787 Proteoglycans Proteins 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- -1 salen metal complex Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000251160 Carcharhinus Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000004510 Collagen Type VII Human genes 0.000 description 1
- 108010017377 Collagen Type VII Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000251125 Prionace glauca Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- UBFRDALTOGELDQ-UHFFFAOYSA-L manganese(2+) 2-methoxyphenol dichloride Chemical compound [Cl-].[Mn+2].C=1(C(O)=CC=CC1)OC.[Cl-] UBFRDALTOGELDQ-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001442 methylidyne group Chemical group [H]C#[*] 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical group CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229940007115 shark cartilage extract Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は、8−ヒドロキシ−2’−デオキシグアノシン形成抑制能およびコラーゲン合成促進能を有する化粧料用原料およびこの化粧料用原料を配合した肌荒れ改善効果の非常に高い化粧料に関する。 The present invention relates to a cosmetic raw material having the ability to suppress the formation of 8-hydroxy-2'-deoxyguanosine and the ability to promote collagen synthesis, and a cosmetic having a very high effect of improving skin roughness by blending this cosmetic raw material.
従来、皮膚外用剤にプロテオグリカンが利用されてきた。例えば、プロテオグリカン抽出液にL−アスコルビン酸リン酸塩を配合した美白化粧料が知られている(特許文献1)。また、皮膚外用剤に用いられるプロテオグリカンとして、サメ軟骨由来のプロテオグリカンを得る方法が知られている(特許文献2)。従来使用されていた牛、豚等の高等動物由来のプロテオグリカンと比べ、サメ軟骨由来のプロテオグリカンは透明性が高く、皮膚外用剤の原料として有効であり、シミ、皺、タルミの改善を目的として、このサメ軟骨由来プロテオグリカンにメラニン生成抑制剤や活性酸素消去作用を有する生薬抽出物を組み合わせることが知られている(特許文献3)。
また、酸化防止剤として、サレン−金属錯体を用いることが知られている(特許文献4)。
Conventionally, proteoglycan has been used as an external preparation for skin. For example, a whitening cosmetic is known in which L-ascorbic acid phosphate is blended in a proteoglycan extract (Patent Document 1). Further, as a proteoglycan used in a skin external preparation, a method for obtaining shark cartilage-derived proteoglycan is known (Patent Document 2). Compared to the proteoglycans derived from higher animals such as cattle and pigs that have been used in the past, shark cartilage-derived proteoglycans are highly transparent and effective as a raw material for external preparations for skin, wrinkles, and tarmi. It is known that this shark cartilage-derived proteoglycan is combined with a melanin production inhibitor and a herbal extract having an active oxygen scavenging action (Patent Document 3).
In addition, it is known to use a salen-metal complex as an antioxidant (Patent Document 4).
皮膚外用剤、特に化粧料において求められる効果は、基本的には実際の年齢より若くみせたいという要求を叶えることである。年齢が高く見える理由には、シミもあるが、皺やタルミが占める割合が高い。皺やタルミの原因として、活性酸素の作用によりDNA中のグアニン塩基が酸化損傷を受けることによる8−ヒドロキシ−2’−デオキシグアノシン(以下、「8−OHdG」という)の形成や、細胞外マトリックス成分であるコラーゲンの減少などが挙げられる。
しかし、8−OHdG形成を抑制すると共にコラーゲン合成を促進することができる化粧料用原料は知られておらず、また、この化粧料用原料を用いて、皺やタルミを減少させて肌荒れ改善効果に優れた化粧料は知られていない。
However, there is no known cosmetic raw material that can suppress 8-OHdG formation and promote collagen synthesis, and this cosmetic raw material can be used to reduce wrinkles and tarmi, thereby improving skin roughness. No good cosmetics are known.
本発明はこのような問題に対処するためになされたもので、特に肌の皺やタルミなどの改善を目的として、8−OHdG形成抑制能およびコラーゲン合成促進能を有する化粧料用原料の提供、およびこの原料を用いることにより肌荒れ改善効果に優れた化粧料の提供を目的とする。 The present invention was made to cope with such problems, and in particular, for the purpose of improving skin wrinkles and talmi, providing a cosmetic raw material having an ability to suppress 8-OHdG formation and an ability to promote collagen synthesis, And it aims at provision of the cosmetics excellent in the rough skin improvement effect by using this raw material.
本発明の化粧料用原料は、サメ軟骨より抽出したプロテオグリカンとエチルビスイミノメチルグアヤコールマンガンクロリドとを含み、8−OHdG形成抑制能およびコラーゲン合成促進能を有することを特徴とする。
また、さらに1種以上のアミノ酸を配合することを特徴とする。上記アミノ酸が、グリシン、グルタミン酸、およびアルギニンから選ばれた少なくとも1つのアミノ酸であることを特徴とする。
The raw material for cosmetics of the present invention contains proteoglycan extracted from shark cartilage and ethylbisiminomethyl guaiacol manganese chloride, and has the ability to suppress 8-OHdG formation and promote collagen synthesis.
Furthermore, it is characterized by further blending one or more amino acids. The amino acid is at least one amino acid selected from glycine, glutamic acid, and arginine.
本発明の化粧料は、上記8−OHdG形成抑制能およびコラーゲン合成促進能を有する化粧料用原料を配合することを特徴とする。 The cosmetic of the present invention is characterized by blending a cosmetic raw material having the above-mentioned 8-OHdG formation inhibitory ability and collagen synthesis promoting ability.
本発明の化粧料用原料は、サメ軟骨より抽出したプロテオグリカンと、サレン金属錯体であるエチルビスイミノメチルグアヤコールマンガンクロリドとを含む。これら2成分を合わせることにより、抗酸化成分である後者の活性酸素を無害化する作用と、前者のマトリックスメタロプロテアーゼ活性を阻害する作用が相乗効果をもたらし、それぞれ単独に用いたものと比較して、優れた8−OHdG形成抑制能を有すると共にコラーゲン合成促進能を有する化粧料用原料が得られる。さらにアミノ酸を配合するので、8−OHdG形成抑制能およびコラーゲン合成促進能が更に向上する。
その結果、この化粧料用原料を配合した化粧料は肌荒れ改善効果が非常に高く、皺に対して非常に有効性が高い。
The cosmetic raw material of the present invention contains proteoglycan extracted from shark cartilage and ethyl biiminomethyl guaiacol manganese chloride, which is a salen metal complex. By combining these two components, the action of detoxifying the latter active oxygen, which is an antioxidant component, and the action of inhibiting the former matrix metalloprotease activity brought about a synergistic effect, compared to those used alone. Thus, a cosmetic raw material having excellent 8-OHdG formation inhibiting ability and collagen synthesis promoting ability is obtained. Furthermore, since an amino acid is blended, the ability to suppress 8-OHdG formation and the ability to promote collagen synthesis are further improved.
As a result, a cosmetic containing this cosmetic raw material has a very high effect on improving rough skin and is very effective against wrinkles.
上記課題に対して研究の結果、サメ軟骨より抽出したプロテオグリカンとエチルビスイミノメチルグアヤコールマンガンクロリドを配合することで問題を解決できた。
プロテオグリカンは蛋白質コアに 100〜200 本のムコ多糖が結合した物質であり、軟骨、皮膚などの結合組織中に存在し、これらの組織構造を維持するために必要な物質である。皮膚外用剤には牛、豚より得られたプロテオグリカンも利用されているが、サメの軟骨より得られたプロテオグリカンの方がマトリックスメタロプロテアーゼ活性を阻害する効果が高かった。本発明の化粧料用原料に使用できるサメの種類に限定はなく、軟骨魚綱に属するサメであればよいが、実際には漁獲高が多く、他の用途にも利用され、漁法が確立しているヨシキリザメ、ネズミザメ、アオザメ等を利用することが多い。これらのサメはその鰭の部分に軟骨が多く、抽出も容易であるが、他のサメや他の部位を用いても問題はない。サメ軟骨からのプロテオグリカンの抽出は常法に従って実施することができる。なお、抽出により得られるプロテオグリカンの純度は特に問題にならないので用途や用法によってその程度を選択することができる。
As a result of research on the above problems, the problem could be solved by adding proteoglycan extracted from shark cartilage and ethylbisiminomethyl guaiacol manganese chloride.
Proteoglycan is a substance in which 100 to 200 mucopolysaccharides are bound to a protein core, is present in connective tissues such as cartilage and skin, and is a substance necessary for maintaining these tissue structures. Proteoglycans obtained from cattle and pigs are also used as topical skin preparations, but proteoglycans obtained from shark cartilage were more effective in inhibiting matrix metalloprotease activity. The type of shark that can be used in the cosmetic raw material of the present invention is not limited, and any shark belonging to the cartilage fish class may be used. Often used are blue sharks, mouse sharks, and gray sharks. These sharks have many cartilage in their wings and can be easily extracted, but there is no problem using other sharks or other parts. Extraction of proteoglycan from shark cartilage can be performed according to a conventional method. In addition, since the purity of proteoglycan obtained by extraction is not particularly problematic, the degree can be selected according to the use and usage.
サメ軟骨よりプロテオグリカンを得る方法を例示すれば、サメの鰭を細断し、水、水と低分子アルコール、塩化ナトリウム、塩化マグネシウム、塩酸グアニジン等の塩の1種または混合物を加えた液を用いて抽出する。
さらに、必要に応じて濃縮、脱塩、脱色、溶媒除去、乾燥(噴霧、凍結)、分子量分画、タンパク分解酵素処理等を行なう。
また、サメ軟骨のプロテオグリカンは化粧品原料として市販されているものを用いることができる。
サメ軟骨より抽出したプロテオグリカンの配合量は用途等によって変化するが、本発明の化粧料用原料全量に対して、固形分として 0.0001〜10 重量%、好ましくは 0.001〜5 重量%配合する。
To illustrate how to obtain proteoglycan from shark cartilage, use a solution obtained by chopping shark wrinkles and adding one or a mixture of water, water and low-molecular alcohol, sodium chloride, magnesium chloride, guanidine hydrochloride and other salts. To extract.
Furthermore, concentration, desalting, decolorization, solvent removal, drying (spraying, freezing), molecular weight fractionation, proteolytic enzyme treatment, etc. are performed as necessary.
As shark cartilage proteoglycans, those commercially available as cosmetic raw materials can be used.
The amount of proteoglycan extracted from shark cartilage varies depending on the application and the like, but is 0.0001 to 10% by weight, preferably 0.001 to 5% by weight as the solid content with respect to the total amount of the cosmetic raw material of the present invention.
サメ軟骨より抽出したプロテオグリカンに加えて、エチルビスイミノメチルグアヤコールマンガンクロリドを配合する。
エチルビスイミノメチルグアヤコールマンガンクロリドは、化学名 Chloro[[2,2'-[1,2-ethanediylbis[(nitrilo-κN)methylidyne]]bis[6-methoxyphenolato-κN]]]-manganese で、市販品としては、ATRIUM社製 商品名 EUK−134などを利用できる。
エチルビスイミノメチルグアヤコールマンガンクロリドの配合量は、本発明の化粧料用原料全量に対し、0.00001〜1.0 重量%、好ましくは 0.0001〜0.1 重量% 配合する。
エチルビスイミノメチルグアヤコールマンガンクロリドは、スーパーオキシドジスムターゼやカタラーゼのような働きがあり、傷害性の高い活性酸素や中間生成物でもある過酸化水素を生体に無害な水と酸素に変換することができ、非常に強い活性酸素消去効果が得られる。また、自己再生特性機能を有し、上記効果を持続して得ることができる。さらには広義の活性酸素である一酸化窒素等の消去作用も有する。
エチルビスイミノメチルグアヤコールマンガンクロリドにサメ軟骨より抽出したプロテオグリカンを加えると、エチルビスイミノメチルグアヤコールマンガンクロリドがもつ遺伝子損傷抑制効果(8−OHdG形成抑制)およびコラーゲン合成促進作用が相乗的に強化された。
In addition to proteoglycan extracted from shark cartilage, ethylbisiminomethyl guaiacol manganese chloride is added.
Ethyl bisiminomethyl guaiacol manganese chloride is commercially available under the chemical name Chloro [[2,2 '-[1,2-ethanediylbis [(nitrilo-κN) methylidyne]] bis [6-methoxyphenolato-κN]]]-manganese. For example, trade name EUK-134 manufactured by ATRIUM can be used.
The compounding amount of ethylbisiminomethyl guaiacol manganese chloride is 0.00001 to 1.0% by weight, preferably 0.0001 to 0.1% by weight, based on the total amount of the cosmetic raw material of the present invention.
Ethylbisiminomethyl guaiacol manganese chloride works like superoxide dismutase and catalase, and can convert highly toxic active oxygen and hydrogen peroxide, which is an intermediate product, into water and oxygen that are harmless to the living body. A very strong active oxygen scavenging effect can be obtained. Moreover, it has a self-regenerative characteristic function and can continuously obtain the above effects. Furthermore, it has an erasing action such as nitric oxide which is active oxygen in a broad sense.
Addition of proteoglycan extracted from shark cartilage to ethyl bisiminomethyl guaiacol manganese chloride synergistically enhanced the effect of ethyl bisiminomethyl guaiacol manganese chloride on inhibition of gene damage (suppression of 8-OHdG formation) and the promotion of collagen synthesis. .
さらに、アミノ酸を配合するとより効果を発揮する。アミノ酸としては、グリシン、アラニン、バリン、ロイシン、イソロイシン、セリン、トレオニン、システイン、メチオニン、プロリン、フェニルアラニン、トリプトファン、チロシンのような中性アミノ酸、グルタミン酸、アスパラギン酸のような酸性アミノ酸、リシン、アルギニン、ヒスチジンのような塩基性アミノ酸が挙げられる。これらの中でグリシン、グルタミン酸、およびアルギニンが好ましい。本発明の化粧料用原料では、これらの1種以上を配合する。本発明者らが検討した結果、複数の種類のアミノ酸を混合して用いると効果が高くなることが判明した。特に、中性アミノ酸、酸性アミノ酸、塩基性アミノ酸のそれぞれ1種以上を配合すると非常に効果的なことがわかった。また、大豆やコラーゲン等の加水分解物のようにアミノ酸が混合させた状態の原料を用いることもできる。 Furthermore, when an amino acid is blended, it is more effective. As amino acids, neutral amino acids such as glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, proline, phenylalanine, tryptophan, tyrosine, acidic amino acids such as glutamic acid, aspartic acid, lysine, arginine, Examples include basic amino acids such as histidine. Of these, glycine, glutamic acid, and arginine are preferred. In the cosmetic raw material of the present invention, one or more of these are blended. As a result of studies by the present inventors, it has been found that the effect is enhanced when a plurality of types of amino acids are used in combination. In particular, it has been found that it is very effective to add one or more of neutral amino acids, acidic amino acids, and basic amino acids. In addition, a raw material in which amino acids are mixed, such as a hydrolyzate such as soybean or collagen, can also be used.
サメ軟骨より抽出したプロテオグリカンは、マトリックスメタロプロテアーゼ(MMP)のうち、MMP−2,MMP−9の活性を阻害する。これらの酵素はVII型コラーゲンやエラスチン等の分解に関与しており、皮膚の細胞外マトリックスを萎縮させる酵素である。これは動物性コラーゲナーゼと呼ばれるが、このほかにも細菌性コラーゲナーゼが存在し、これらに対してアミノ酸が有効であることが知られている。また、サメ軟骨より抽出したプロテオグリカンとアミノ酸を組み合わせることにより、多くの種類のマトリックスメタロプロテアーゼの作用を抑制し、皮膚のマトリックスであるコラーゲンの合成を促進して、コラーゲンの維持や強化を行ない、皺の予防、減少、タルミの防止等を効果的に行なうことができる。
エチルビスイミノメチルグアヤコールマンガンクロリドおよびサメ軟骨より抽出したプロテオグリカンに、さらにアミノ酸を配合することによって、8−OHdG形成抑制能、および特にコラーゲン合成促進作用が相乗的に効果を増すことが本発明者によって見出された。
Proteoglycan extracted from shark cartilage inhibits the activities of MMP-2 and MMP-9 among matrix metalloproteases (MMP). These enzymes are involved in the degradation of type VII collagen and elastin, and are enzymes that atrophy the extracellular matrix of the skin. This is called animal collagenase, but there are other bacterial collagenases, and amino acids are known to be effective against these. In addition, combining proteoglycan extracted from shark cartilage and amino acids suppresses the action of many types of matrix metalloproteases, promotes the synthesis of collagen, the skin matrix, maintains and strengthens collagen, It is possible to effectively prevent, reduce and prevent tarmi.
According to the present inventor, by adding an amino acid to proteoglycan extracted from ethylbisiminomethyl guaiacol manganese chloride and shark cartilage, the ability to suppress 8-OHdG formation, and particularly the action of promoting collagen synthesis, synergistically increases the effect. It was found.
アミノ酸の配合量は、用途、用法によって大きく異なるので、一概には示すことはできないが、本発明の化粧料原料全量に対し、0.1〜5 重量%程度配合されることが好ましい。 The amount of amino acid varies greatly depending on the application and usage, and cannot be generally shown, but it is preferably about 0.1 to 5% by weight based on the total amount of the cosmetic raw material of the present invention.
上述した化粧料用原料のほかに必要な原料を加えて、化粧料を作製する。その中で、他の有効性物質、例えば、アスコルビン酸およびその誘導体、ビタミンAおよびその誘導体、類似体、ヒアルロン酸およびその塩、各種植物抽出物等を併用することは本発明の付加価値を高めるので配合することがより好ましい。
また本発明の化粧料は、用途等によって、クリーム、乳液、ローション、パック、スプレー、ジェル等任意の剤型より選択することは、なんら問題はない。また、医薬品、医薬部外品、化粧品のいずれでもよく、皮膚に適用するものであれば、入浴剤、ファンデーション等の形態をとってもよい。
In addition to the cosmetic raw materials described above, the necessary raw materials are added to produce cosmetics. Among them, the combined use of other effective substances such as ascorbic acid and its derivatives, vitamin A and its derivatives, analogs, hyaluronic acid and its salts, various plant extracts, etc. increases the added value of the present invention. Therefore, it is more preferable to mix them.
Moreover, there is no problem in selecting the cosmetics of the present invention from arbitrary dosage forms such as creams, emulsions, lotions, packs, sprays, gels, etc. depending on applications. Moreover, any of pharmaceuticals, quasi-drugs, and cosmetics may be used. As long as they are applied to the skin, forms such as bathing agents and foundations may be used.
以下に実施例を記載するが、当然これに限定させるものではない。なお、以下表中の配合量は重量部で表した。 Although an Example is described below, naturally it is not limited to this. In addition, the compounding quantity in the following table | surface was represented by the weight part.
実施例1〜実施例4および比較例1〜比較例4
表1および表2に示す原料を、表1および表2に示す配合割合で攪拌混合し、化粧料用原料を得た。なお、サメ軟骨抽出液はAETERNA社製 商品名 MDICOMPLEX(有効成分含量: 0.4 重量%)を用いた。また、エチルビスイミノメチルグアヤコールマンガンクロリドとして、ATRIUM社製 商品名 EUK−134(有効成分含量: 95 重量%以上)を用いた。
得られた化粧料用原料を用いて、以下に示す8−OHdG形成抑制試験およびコラーゲン合成促進試験を行なった。
Examples 1 to 4 and Comparative Examples 1 to 4
The raw materials shown in Tables 1 and 2 were stirred and mixed at the blending ratios shown in Tables 1 and 2 to obtain cosmetic raw materials. The shark cartilage extract used was trade name MDICOMPLEX (active ingredient content: 0.4% by weight) manufactured by AETERA. As ethylbisiminomethyl guaiacol manganese chloride, trade name EUK-134 (active ingredient content: 95% by weight or more) manufactured by ATRIUM was used.
Using the obtained cosmetic raw material, the following 8-OHdG formation inhibition test and collagen synthesis promotion test were conducted.
試験1 8−OHdG形成抑制試験
ヒト由来のケラチノサイト培養細胞を使用し、上述の実施例1〜4および比較例1〜4の化粧料用原料を用いて、8−OHdG形成抑制効果を調べた。
各実施例および比較例の化粧料用原料の最終濃度が 0.01 %または 0.1 %になるようにした培地で4日間培養した。その後、それぞれ 0 mJ/cm2(未照射)、50 mJ/cm2、100 mJ/cm2 の紫外線を照射し、ケラチノサイトからDNAを抽出し、イムノドットブロット法を用いて、8−OHdG形成率を測定した。
Test 1 8-OHdG formation inhibition test Using human-derived keratinocyte cultured cells, the 8-OHdG formation inhibition effect was examined using the cosmetic raw materials of Examples 1 to 4 and Comparative Examples 1 to 4 described above.
Each of the examples and comparative examples was cultured for 4 days in a medium in which the final concentration of the cosmetic raw material was 0.01% or 0.1%. Thereafter, ultraviolet rays of 0 mJ / cm 2 (unirradiated), 50 mJ / cm 2 and 100 mJ / cm 2 were irradiated to extract DNA from keratinocytes, and 8-OHdG formation rate using immunodot blotting Was measured.
また、同様に育成した培養細胞をホルマリン固定後、1 %クリスタルバイオレット溶液に添加し染色した。各化粧料用原料の各濃度に対する細胞育成率を、モノセレーター(オリンパス社製)で測定した。
これらの結果を表3〜表10に示す。表中、数値は8−OHdG形成率を、また括弧内の数値は細胞育成率を示し、いずれも実施例(または比較例)を含まない紫外線量が0 mJ/cm2(未照射)のときを1として表示した。
Similarly, cultured cells grown in the same manner were fixed in formalin, added to a 1% crystal violet solution and stained. The cell growth rate for each concentration of each cosmetic raw material was measured with a monocerator (manufactured by Olympus).
These results are shown in Tables 3 to 10. In the table, the numerical value indicates the 8-OHdG formation rate, and the numerical value in parentheses indicates the cell growth rate. When the amount of ultraviolet rays does not include any example (or comparative example) is 0 mJ / cm 2 (unirradiated) Was displayed as 1.
実施例1〜4の化粧料用原料を用いた培地で培養した細胞では比較例を用いた細胞に比べて、紫外線量を増大しても8−OHdG形成が行なわれにくく、優れた8−OHdG形成抑制効果がみられた。また、実施例1〜4を用いた培地で培養したものは比較例を用いたものに比べて、紫外線量を増大しても細胞育成率の低下率が低く、細胞育成能の劣化についても抑制効果がみられた。 In cells cultured in a medium using the cosmetic raw materials of Examples 1 to 4, 8-OHdG formation is less likely to occur even when the amount of ultraviolet rays is increased, compared to cells using Comparative Examples, and excellent 8-OHdG A formation inhibitory effect was observed. Moreover, compared with the thing using the comparative example, even if it increased the amount of ultraviolet rays, the fall rate of the cell growth rate was low and what was cultured with the culture medium using Examples 1-4 also suppressed deterioration of cell growth ability. The effect was seen.
試験2 コラーゲン合成促進試験
ヒト皮膚線維芽細胞(ATCC CCL 110)を用い、96穴プレートにヒト皮膚線維芽細胞を 5000 cells/well 播種し、10 %ウシ胎仔血清を含むEagle's MEM培地にて、37 ℃、5 % CO2条件下でコンフルエントの状態になるまで4日間培養した。これに実施例1〜4および比較例1〜4を、培養濃度を 1.0 %となるように調整した無血清のEagle's MEM( 50 μg/ml L−アスコルビン酸、50 μg/ml β−アミノプロピオニトリル、18.5 KBq 3H−プロリン含有)に交換し、24時間培養した。その後、直ちに各 well にペプシン溶液を加えインキュベーションした後、3H−プロリン標識されたコラーゲンを抽出した。塩析により精製した後、コラーゲンタンパク中の放射活性を液体シンチレーションカウンターにより測定した。各試料とも 5 well ずつ測定し、試料無添加のものをコントロールとして用い、これを1としてコラーゲン合成促進倍率を表した。結果を表11に示す。
Test 2 Collagen synthesis promotion test Human skin fibroblasts (ATCC CCL 110) were used to seed 5000 cells / well of human skin fibroblasts in a 96-well plate, and in Eagle's MEM medium containing 10% fetal bovine serum. The cells were cultured for 4 days at 37 ° C. under 5% CO 2 until they became confluent. To this, Examples 1 to 4 and Comparative Examples 1 to 4 were serum-free Eagle's MEM (50 μg / ml L-ascorbic acid, 50 μg / ml β-amino) adjusted to a culture concentration of 1.0%. The mixture was replaced with propionitrile (containing 18.5 KBq 3H-proline) and cultured for 24 hours. Then, immediately after adding a pepsin solution to each well and incubating, 3H-proline labeled collagen was extracted. After purification by salting out, the radioactivity in the collagen protein was measured with a liquid scintillation counter. Each sample was measured in 5 wells, and the sample-free sample was used as a control. The results are shown in Table 11.
実施例1〜4では、比較例に比べ、コラーゲン合成促進倍率において良好な結果を得た。特に、アミノ酸であるグリシン、グルタミン酸およびアルギニンの3種全てを使用した実施例4では、優れたコラーゲン合成促進能を有していた。 In Examples 1 to 4, good results were obtained in the collagen synthesis promotion magnification as compared with Comparative Examples. In particular, Example 4 using all three amino acids glycine, glutamic acid, and arginine had excellent ability to promote collagen synthesis.
実施例5〜実施例8および比較例5〜比較例6
表12および表13に示す配合で、A成分とB成分とをそれぞれ計量し、それぞれを 70 ℃まで加温して、B成分にA成分を攪拌しつつ徐々に加えたのち、ゆっくり攪拌しつつ 30 ℃まで冷却して化粧料を得た。
得られた化粧料を用いて、以下に示す肌荒れ改善試験を行なった。
Examples 5 to 8 and Comparative Examples 5 to 6
In the formulations shown in Table 12 and Table 13, the A component and the B component were weighed, each was heated to 70 ° C., and the A component was gradually added to the B component while stirring, and then slowly stirred. A cosmetic was obtained by cooling to 30 ° C.
Using the resulting cosmetic, the following rough skin improvement test was conducted.
試験3 肌荒れ改善試験
ハイドロフィリック エクザフレックス親水性ビニルシリコーン印象材を用いて、女性健常人の顔面の皮膚表面形態のレプリカを取り、実態顕微鏡にて観察した。表14に示す基準に従って肌荒れ評価4と5と判断された者60名を3班に分け、顔面左右半々に、実施例および比較例を1日2回ずつ1ヶ月間塗布した。
1ヶ月後、再び上記のレプリカ法によって顔面の皮膚表面形態を観察し、表14の判定基準に従って評価した。第1班の結果を表15に、第2班の結果を表16に、第3班の結果を表17に示す。
Test 3 Rough skin improvement test Hydrophilic Exaflex hydrophilic vinyl silicone impression material was used to take a replica of the skin surface morphology of a healthy female face and observed with a microscope. According to the criteria shown in Table 14, 60 persons judged to have rough skin evaluations 4 and 5 were divided into 3 groups, and Examples and Comparative Examples were applied to the left and right halves of the face twice a day for 1 month.
One month later, the skin surface morphology of the face was again observed by the above replica method, and evaluated according to the criteria shown in Table 14. The results of the first team are shown in Table 15, the results of the second team are shown in Table 16, and the results of the third team are shown in Table 17.
本発明の化粧料用原料は、8−OHdG形成抑制能およびコラーゲン合成促進能を有するため、肌荒れ改善効果の非常に高い化粧料を得ることができ、クリーム、乳液、ローション、パック、スプレー、ジェル、入浴剤、ファンデーション等の化粧品、医薬品、または医薬部外品として好適に利用できる。 Since the raw material for cosmetics of the present invention has an ability to suppress 8-OHdG formation and promotes collagen synthesis, it can obtain a cosmetic with a very high effect of improving rough skin, such as cream, emulsion, lotion, pack, spray, gel. , Bathing agents, foundations and other cosmetics, pharmaceuticals, or quasi-drugs.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007250957A JP4753922B2 (en) | 2007-09-27 | 2007-09-27 | Raw materials for cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007250957A JP4753922B2 (en) | 2007-09-27 | 2007-09-27 | Raw materials for cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009079016A true JP2009079016A (en) | 2009-04-16 |
| JP4753922B2 JP4753922B2 (en) | 2011-08-24 |
Family
ID=40654059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007250957A Active JP4753922B2 (en) | 2007-09-27 | 2007-09-27 | Raw materials for cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4753922B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017048151A (en) * | 2015-09-03 | 2017-03-09 | 地方独立行政法人青森県産業技術センター | Collagen gel contraction promoter, anti-glycation agent and skin external preparation |
| JP2019011259A (en) * | 2017-06-29 | 2019-01-24 | 肇 小座野 | Filaggrin production promoter, loricrin production promoter, involucrin production promoter |
| JP2020125319A (en) * | 2015-09-03 | 2020-08-20 | 地方独立行政法人青森県産業技術センター | Anti-glycation agent and external skin preparation |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507646A (en) * | 1995-06-07 | 1999-07-06 | ユーカリオン,インコーポレイティド | Synthetic catalytic free radical scavengers useful as antioxidants for disease prevention and treatment |
| JP2000229836A (en) * | 1999-02-12 | 2000-08-22 | Pola Chem Ind Inc | Skin lotion composition for suppressing skin |
| JP2003002819A (en) * | 2001-06-22 | 2003-01-08 | Naris Cosmetics Co Ltd | Skin care composition |
| JP2003300858A (en) * | 2002-04-09 | 2003-10-21 | Nonogawa Shoji Kk | Skin care preparation |
| JP2005170805A (en) * | 2003-12-08 | 2005-06-30 | Chanson Keshohin Kk | Skin care cosmetic, cosmetic set thereof and method for using them |
| JP2005239698A (en) * | 2004-02-27 | 2005-09-08 | Hajime Kozano | Skin care preparation for external use |
| JP2006316028A (en) * | 2005-05-16 | 2006-11-24 | Maruzen Pharmaceut Co Ltd | Antiaging agent and epidermal keratinizing cell proliferation accelerator |
| US20070189992A1 (en) * | 2002-11-29 | 2007-08-16 | Bioderm Research | Sunscreen Safety and Efficacy Enhancement with Manganese Complexes via Urocanate Pathway |
-
2007
- 2007-09-27 JP JP2007250957A patent/JP4753922B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507646A (en) * | 1995-06-07 | 1999-07-06 | ユーカリオン,インコーポレイティド | Synthetic catalytic free radical scavengers useful as antioxidants for disease prevention and treatment |
| JP2000229836A (en) * | 1999-02-12 | 2000-08-22 | Pola Chem Ind Inc | Skin lotion composition for suppressing skin |
| JP2003002819A (en) * | 2001-06-22 | 2003-01-08 | Naris Cosmetics Co Ltd | Skin care composition |
| JP2003300858A (en) * | 2002-04-09 | 2003-10-21 | Nonogawa Shoji Kk | Skin care preparation |
| US20070189992A1 (en) * | 2002-11-29 | 2007-08-16 | Bioderm Research | Sunscreen Safety and Efficacy Enhancement with Manganese Complexes via Urocanate Pathway |
| JP2005170805A (en) * | 2003-12-08 | 2005-06-30 | Chanson Keshohin Kk | Skin care cosmetic, cosmetic set thereof and method for using them |
| JP2005239698A (en) * | 2004-02-27 | 2005-09-08 | Hajime Kozano | Skin care preparation for external use |
| JP2006316028A (en) * | 2005-05-16 | 2006-11-24 | Maruzen Pharmaceut Co Ltd | Antiaging agent and epidermal keratinizing cell proliferation accelerator |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017048151A (en) * | 2015-09-03 | 2017-03-09 | 地方独立行政法人青森県産業技術センター | Collagen gel contraction promoter, anti-glycation agent and skin external preparation |
| JP2020125319A (en) * | 2015-09-03 | 2020-08-20 | 地方独立行政法人青森県産業技術センター | Anti-glycation agent and external skin preparation |
| JP2019011259A (en) * | 2017-06-29 | 2019-01-24 | 肇 小座野 | Filaggrin production promoter, loricrin production promoter, involucrin production promoter |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4753922B2 (en) | 2011-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2421262T3 (en) | Composition for personal and cosmetic care containing tetrapeptides with CX1X2G, PX1X2P or PX1X2K units | |
| JP2000095663A (en) | Agent for external use containing plant extract | |
| JP2010132639A (en) | Dna damage inhibitor and matrix metalloprotease-1 production inhibitor | |
| JP2006131633A (en) | Use of urea compounds to suppress signs of skin aging | |
| KR100977672B1 (en) | Cosmetic composition for anti-aging comprising the cellular vital complex as active ingredient | |
| US20070190175A1 (en) | Skin care composition for dermatological disorders | |
| JP2002534454A (en) | Use of a plant extract of Rosmarinus in a composition for treating the signs of aging skin | |
| JP4753922B2 (en) | Raw materials for cosmetics | |
| US8173144B2 (en) | Administration of urea compounds for combating signs of cutaneous aging | |
| JP2006348035A (en) | Preparation suitable for external application | |
| WO2007075016A1 (en) | Collagenase inhibitor containing poly-gamma-glutamic acid-vitamin c complex and use thereof | |
| JPH0532533A (en) | Cosmetics | |
| KR101945349B1 (en) | Cosmetic composition comprising substance P for improving skin wrinkles or anti-inflammation activity | |
| JP6836874B2 (en) | Hair restorer composition and vascular endothelial growth factor production promoter | |
| KR20080040612A (en) | Method for screening skin external composition and anti-aging material containing cathepsin 텝 inhibitor | |
| JP5423002B2 (en) | Collagen synthesis promoter containing zinc as an active ingredient | |
| JPH11240817A (en) | Beauty culture pack | |
| JP2000344653A (en) | Eraser for active oxygen and skin cosmetic | |
| KR100472919B1 (en) | Water soluble whitening composition and cosmetic composition for whitening skin comprising the same | |
| JPH0912432A (en) | Hair restoration / hair restoration | |
| JP2005239698A (en) | Skin care preparation for external use | |
| JP3023543B2 (en) | Tyrosinase activity inhibitor and cosmetic | |
| JP4842550B2 (en) | Tyrosinase activity inhibitor, melanin production inhibitor, and skin whitening external preparation | |
| JP6853547B2 (en) | Composition for inhibiting collagen degradation | |
| RU2355383C2 (en) | Microbial collagenase makeup preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100810 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101008 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110510 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110524 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20200603 Year of fee payment: 9 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4753922 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |